ZA201604370B - Prostate cancer gene profiles and methods of using the same - Google Patents

Prostate cancer gene profiles and methods of using the same

Info

Publication number
ZA201604370B
ZA201604370B ZA2016/04370A ZA201604370A ZA201604370B ZA 201604370 B ZA201604370 B ZA 201604370B ZA 2016/04370 A ZA2016/04370 A ZA 2016/04370A ZA 201604370 A ZA201604370 A ZA 201604370A ZA 201604370 B ZA201604370 B ZA 201604370B
Authority
ZA
South Africa
Prior art keywords
methods
same
prostate cancer
cancer gene
gene profiles
Prior art date
Application number
ZA2016/04370A
Other languages
English (en)
Inventor
Shiv K Srivastava
Albert Dobi
Gyorgy Petrovics
Thomas Werner
Martin Seifert
Matthias Scherf
Original Assignee
Henry M Jackson Found Advancement Military Medicine Inc
Genomatix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M Jackson Found Advancement Military Medicine Inc, Genomatix filed Critical Henry M Jackson Found Advancement Military Medicine Inc
Publication of ZA201604370B publication Critical patent/ZA201604370B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57434Specifically defined cancers of prostate
    • G01N33/57555
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2016/04370A 2013-12-30 2016-06-28 Prostate cancer gene profiles and methods of using the same ZA201604370B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361921739P 2013-12-30 2013-12-30
PCT/US2014/072610 WO2015103166A1 (en) 2013-12-30 2014-12-29 Prostate cancer gene profiles and methods of using the same

Publications (1)

Publication Number Publication Date
ZA201604370B true ZA201604370B (en) 2020-12-23

Family

ID=53493959

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2016/04370A ZA201604370B (en) 2013-12-30 2016-06-28 Prostate cancer gene profiles and methods of using the same

Country Status (8)

Country Link
US (1) US20160326594A1 (enExample)
EP (1) EP3090265B1 (enExample)
JP (1) JP2017509351A (enExample)
CN (1) CN106796236A (enExample)
AU (1) AU2014373927B2 (enExample)
CA (1) CA2934828A1 (enExample)
WO (1) WO2015103166A1 (enExample)
ZA (1) ZA201604370B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US11332794B2 (en) 2016-01-19 2022-05-17 Wayne State University Prostate cancer aggressiveness gene signatures for subjects of African or European descent
CA3062573A1 (en) * 2017-05-12 2018-11-15 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer gene profiles and methods of using the same
US11530451B2 (en) * 2018-03-02 2022-12-20 The Johns Hopkins University Methods for prostate cancer detection
CN110054674B (zh) * 2019-03-07 2022-08-05 深圳市龙华区人民医院 免疫原性多肽以及抗ttc36抗体ap2-19及应用
CN110628908B (zh) * 2019-09-19 2022-05-10 北京恩泽康泰生物科技有限公司 用于前列腺癌诊断分级和良恶性预测的生物标志物及检测试剂盒
CN111893177B (zh) * 2020-08-19 2022-10-04 南通大学 遗传性耳聋诱导基因的突变筛选方法及突变检测试剂盒
CN113284559B (zh) * 2021-07-21 2021-10-15 暨南大学 一种物种基因组的启动子查询方法、系统及设备

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US20050032065A1 (en) * 2002-06-24 2005-02-10 Afar Daniel E. H. Methods of prognosis of prostate cancer
US20040191783A1 (en) * 2003-03-31 2004-09-30 Guy Leclercq Low density micro-array analysis in human breast cancer
WO2005113816A2 (en) * 2004-05-07 2005-12-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
AU2005308594A1 (en) * 2004-11-24 2006-06-01 St George's Enterprises Limited Diagnosis of prostate cancer
AU2006292212A1 (en) * 2005-09-19 2007-03-29 The Johns Hopkins University Biomarker for prostate cancer
WO2008058018A2 (en) * 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
JP2010509598A (ja) * 2006-11-13 2010-03-25 ライフ テクノロジーズ コーポレーション 前立腺癌バイオマーカーを検出するための方法およびキット
CA2719172C (en) * 2008-04-10 2020-08-25 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer-specific alterations in erg8 gene expression and detection and treatment methods based on those alterations
US20110236903A1 (en) * 2008-12-04 2011-09-29 Mcclelland Michael Materials and methods for determining diagnosis and prognosis of prostate cancer
FR2945820A1 (fr) * 2009-05-25 2010-11-26 Univ Clermont Auvergne Panel de genes pour le pronostic du cancer de la prostate
BR112012025593A2 (pt) * 2010-04-06 2019-06-25 Caris Life Sciences Luxembourg Holdings biomarcadores em circulação para doença
EP2913405B1 (en) * 2010-07-27 2016-11-09 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer
EP2606353A4 (en) * 2010-08-18 2014-10-15 Caris Life Sciences Luxembourg Holdings CIRCULATING BIOMARKERS FOR DISEASES
US20140045915A1 (en) * 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
EP2514836B1 (en) * 2011-04-19 2016-06-29 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Prostate cancer markers
AU2012252426A1 (en) * 2011-05-12 2013-11-28 Noviogendix Research B.V. Molecular markers in prostate cancer
CN103874770A (zh) * 2011-08-08 2014-06-18 卡里斯生命科学卢森堡控股有限责任公司 生物标志物组合物和方法
CA2844793A1 (en) * 2011-08-31 2013-03-07 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of cancer
SE536352C2 (sv) * 2011-10-24 2013-09-03 Chundsell Medicals Ab Markörgener för klassificiering av prostatacancer
AU2012331104B2 (en) * 2011-11-04 2018-03-15 Mdxhealth Research B.V. Combinations of molecular markers in prostate cancer providing a diagnostic tool with improved sensitivity/specificity
US9863002B2 (en) * 2012-06-04 2018-01-09 North Carolina Central University Genetic determinants of prostate cancer risk

Also Published As

Publication number Publication date
WO2015103166A1 (en) 2015-07-09
US20160326594A1 (en) 2016-11-10
CN106796236A (zh) 2017-05-31
EP3090265A4 (en) 2018-03-21
AU2014373927B2 (en) 2018-03-22
EP3090265B1 (en) 2020-04-08
JP2017509351A (ja) 2017-04-06
AU2014373927A1 (en) 2016-07-07
EP3090265A1 (en) 2016-11-09
CA2934828A1 (en) 2015-07-09

Similar Documents

Publication Publication Date Title
IL273090B (en) Methods and preparations for the treatment of cancer
EP3062808A4 (en) Treatment of metastatic prostate cancer
IL244510A0 (en) Cancer biomarkers and their uses
ZA201505735B (en) Cancer drug and uses
IL234462B (en) Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
IL234581B (en) Systems for heating with amplified microwaves and methods for using them
GB201322725D0 (en) Cancer therapy
ZA201604370B (en) Prostate cancer gene profiles and methods of using the same
EP2967503A4 (en) Systems and methods for treating prostate cancer
SG11201508223YA (en) Treatment of cancer with dihydropyrazino-pyrazines
ZA201604369B (en) Genomic rearrangements associated with prostate cancer and methods of using the same
SG11201509707QA (en) Cancer therapy
ZA201507733B (en) Treatment of cancer with dihydropyrazino-pyrazines
SG11201508878WA (en) Methods of treating cancer
EP2965086A4 (en) Methods of detecting prostate cancer
SG11201507847UA (en) Cancer therapy
EP2970419B8 (en) Methods of treating colorectal cancer
EP3058067A4 (en) Circulating cancer biomarker and its use
GB201314485D0 (en) Materials and methods relating to pancreatic cancer
ZA201507762B (en) Methods of treating cancer
EP2961412A4 (en) CANCER THERAPY
EP3024499A4 (en) Model of colorectal cancer
SG11201509367RA (en) Methods for predicting and improving the survival of colorectal cancer patients
GB201303115D0 (en) Detection and treatment of liver cancer
GB201317213D0 (en) Cancer Therapy